title: Long-term naringin consumption reverses a glucose uptake defect and improves  cognitive deficits in a mouse model of Alzheimer's disease.
abstract: Naringin, a bioflavonoid, has been reported to have potent neuro-protective effects, but its preventive effects on amyloid-β (Aβ) induced, Alzheimer's disease (AD) related, cognitive impairment, and the underlying mechanisms of these effects have not been well characterised. Three-month-old APPswe/PSΔE9 transgenic mice were randomly assigned to a vehicle group, two naringin (either 50 or 100 mg/kg/day) groups, or an Aricept (2 mg/kg/day) group. After 16 weeks of treatment, we observed beneficial effects of naringin (100 mg/kg/day), including lessening learning and memory deficits, improving locomotor activity, reducing scattered senile plaques, and ameliorating disturbances in brain energy metabolism. Furthermore, GSK-3β phosphorylation significantly increased in the naringin-treated (100 mg/kg/day) group. These findings suggest that a reduction in plaque burden and an increase in glucose uptake through the inhibition of GSK-3β activity may be one of the mechanisms by which naringin improves cognitive functioning in the APPswe/ PSΔE9 transgenic mouse model of Alzheimer's disease.
authors: Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, China.
authors: Dongmei
authors: D
authors: Wang
authors: Kai
authors: K
authors: Gao
authors: Xiaoying
authors: X
authors: Li
authors: Xinhua
authors: X
authors: Shen
authors: Xu
authors: X
authors: Zhang
authors: Chunmei
authors: C
authors: Ma
authors: Chuan
authors: C
authors: Qin
authors: Lianfeng
authors: L
authors: Zhang
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D003072:Cognition Disorders / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D044950:Flavanones / Q000008:administration & dosage*; D005947:Glucose / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011897:Random Allocation; D013997:Time Factors
chemical_list: D044950:Flavanones; D005947:Glucose; C005274:naringin